Gene expression patterns in the histopathological classifcation of epithelial ovarian cancer

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 187-192

  Zhu, Honglan ^a,b   Yu, Jing Jie ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Epithelial ovarian cancer; Gene signature; Histopathological types; Real time quantitative pcr

Indexed keywords

EPIDERMAL GROWTH FACTOR; INSULIN RECEPTOR; INTERLEUKIN ENHANCER BINDING FACTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; RAD52 PROTEIN; SCRAMBLASE; SINGLE STRANDED DNA BINDING PROTEIN; THIOREDOXIN REDUCTASE 1; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR TAL1; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME E21; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SCREENING; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DNA REPAIR; EPITHELIAL OVARIAN CANCER; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE; OVARY CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SUMOYLATION; UBIQUITINATION;

EID: 77955764847     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000030     Document Type: Article

References (25)

1. Shih IM and Kurman RJ: Ovarian Tumorigenesis. Am J Pathol 164: 1511-1518, 2004.
2. Baranova A, Gowder S, Naouar S, et al: Expression Profle of Ovarian tumors distinct signature of Sertoli-leydig cell tumor. Int J Gynecol Cancer 16: 1963-1972, 2006.
3. Yu JJ: Unlocking the Molecular mechanisms of DNA Repair and platinum drug resistance in cancer chemotherapy. Curr DRug Ther 4: 19-28, 2009.
4. Bell DA: Origins and Molecular pathology of ovarian Cancer. Mod Pathol 18: 19-32, 2005.
5. Cecco LD, Marchionni L, Gariboldi M, et al: Gene Expression Profling of Advanced Ovarian cancer characterization of a molecular signature involving fbroblast growth factor 2. Oncogene 23: 8171-8183, 2004.
6. Tothill RW, Tinker AV, Joshy G, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208, 2008.
7. Reed E, Yu JJ, Davies A, Gannon J and Armentrout SL: Clear cell tumors have higher mrna levels of ercc1 and xpB than other histological types of epithelial ovarian cancer. Clin Cancer Res 9: 5299-5305, 2003.
8. Schwartz DR, Kardia SLR, Shedden KA, et al: Gene expression in ovarian cancer refects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729, 2002.
9. Fehrmann RS, Li XY, van der Zee AG, de Jong S, Te Meerman GJ, de Vries EG and Crijns AP: Profling studies in ovarian cancer: A review. The Oncologist 12: 960-966, 2007.
10. Yu JJ, Dabholkar M, Bennett WP, Welsh JA, Mu CJ, Bostick-Bruton F and Reed E: platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mrna levels of p53, ercc1 and xpa. Int J Oncol 8: 313-317, 1996.
11. Pinheiro P, Gering M and Patient R: The basic helix-loop-helix transcription factor, TAL2, marks the lateral foor plate of the spinal cord in zebrafsh. Gene Expr Patterns 4: 85-92, 2004.
12. Bucher K, Sofroniew MV, Pannell R, et al: The t cell oncogene tal2 is necessary for normal development of the mouse brain. Dev Biol 227: 533-544, 2000.
13. Ferrando AA, Neuberg DS, Staunton J, et al: Gene expression signatures defne novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer cell 1: 75-87, 2002.
14. Wong AST and Leung PCK: Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res 33: 3-16, 2007.
15. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S and Auersperg N: Molecular pathways regulating egF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290: 1532-1542, 2006.
16. Stromberg K, Johnson GR, O'connor DM, Sorensen CM, Gullick WJ and Kannan B: Frequent immunohistochemical detection of egF supergene family members in ovarian carcino-genesis. Int J Gynecol Pathol 13: 342-347, 1994.
17. Niikura H, Sasano H, Sato SH and Yajima A: Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 16: 60-68, 1997.
18. Cazanove O, Batut J, Scarlett G, et al: Methylation of xilF3 by xprmt1b alters its dna, but not rna, binding activity. Biochemistry 47: 8350-8357, 2008.
19. Saunders LR and Barber GN: The dsrna binding protein family: critical roles, diverse cellular functions. FASEB J 17: 961-983, 2003.
20. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK and Claffey KP: Double-stranded rna-binding protein regulates vascular endothelial growth factor mrna stability, translation and breast cancer angiogenesis. Mol Cell Biol 28: 772-783, 2008.
21. Schumacher JJ, Dings RPM, Cosin J, Subramanian IV, Auersperg N and Ramakrishnan S: Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer res 67: 3683-3690, 2007.
22. Bermudez Y, Yang H, Saunders BO, Cheng JQ, Nicosia SV and Kruk PA: VegF- and lpa-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol Oncol 106: 526-537, 2007.
23. Moschos SJ and Mo YY: Role of SumO/ubc9 in dna damage repair and tumorigenesis. J Mol Hist 37: 309-319, 2006.
24. Mo YY, Yu Y, Theodosiou E, Ee PL and Beck WT: A role for ubc9 in tumorigenesis. Oncogene 24: 2677-2683, 2005.
25. Dunnebier T, Bermejo JL, Haas S, et al: Common variants in the uBc9 gene encoding the SumO-conjugating enzyme are associated with breast tumor grade. Int J Cancer 125: 596-602, 2009.